Lipocine Stock Performance
| LPCN Stock | USD 8.72 0.09 1.02% |
Lipocine holds a performance score of 24 on a scale of zero to a hundred. The company secures a Beta (Market Risk) of -0.2, which conveys not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Lipocine are expected to decrease at a much lower rate. During the bear market, Lipocine is likely to outperform the market. Use Lipocine value at risk, as well as the relationship between the skewness and day median price , to analyze future returns on Lipocine.
Risk-Adjusted Performance
Solid
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Lipocine are ranked lower than 24 (%) of all global equities and portfolios over the last 90 days. In spite of very conflicting fundamental indicators, Lipocine displayed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (1.02) | Five Day Return 11.22 | Year To Date Return 9 | Ten Year Return (93.70) | All Time Return (94.87) |
Last Split Factor 1:17 | Last Split Date 2023-05-12 |
1 | Lipocine Highlights Promising Interim Safety Profile in Phase 3 Trial of LPCN 1154 in Postpartum Depression | 11/18/2025 |
2 | H.C. Wainwright Maintains Lipocine With Buy Rating, Cuts Target Price to 7 - | 11/20/2025 |
3 | Lipocine Showcases LPCN 2101 at Epilepsy Meeting - TipRanks | 12/11/2025 |
4 | Head to Head Contrast Astellas Pharma Lipocine | 12/16/2025 |
5 | Acquisition by Mahesh Patel of 25000 shares of Lipocine at 8.0 subject to Rule 16b-3 | 01/02/2026 |
6 | What analysts say about Lipocine Inc stock - Global Trade Effects High Return Wealth Building - earlytimes.in | 01/06/2026 |
7 | Lipocine Reports Encouraging Progress Post Second Interim Safety Review in Phase 3 Trial of LPCN 1154 in Postpartum Depression | 01/12/2026 |
8 | Lipocine Announces Completion of Enrollment and Dosing in Phase 3 Trial of LPCN 1154 in Postpartum Depression | 01/20/2026 |
9 | Buy Rating Maintained on Lipocine Inc. as Target Climbs to 15 | 02/11/2026 |
| Begin Period Cash Flow | 4.8 M | |
| Total Cashflows From Investing Activities | 2.4 M |
Lipocine Relative Risk vs. Return Landscape
If you would invest 287.00 in Lipocine on November 14, 2025 and sell it today you would earn a total of 585.00 from holding Lipocine or generate 203.83% return on investment over 90 days. Lipocine is currently generating 2.0894% in daily expected returns and assumes 6.8811% risk (volatility on return distribution) over the 90 days horizon. In different words, 61% of stocks are less volatile than Lipocine, and 58% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Lipocine Target Price Odds to finish over Current Price
The tendency of Lipocine Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 8.72 | 90 days | 8.72 | about 18.06 |
Based on a normal probability distribution, the odds of Lipocine to move above the current price in 90 days from now is about 18.06 (This Lipocine probability density function shows the probability of Lipocine Stock to fall within a particular range of prices over 90 days) .
Lipocine Price Density |
| Price |
Predictive Modules for Lipocine
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Lipocine. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Lipocine's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Lipocine Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Lipocine is not an exception. The market had few large corrections towards the Lipocine's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Lipocine, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Lipocine within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 2.05 | |
β | Beta against Dow Jones | -0.2 | |
σ | Overall volatility | 2.99 | |
Ir | Information ratio | 0.29 |
Lipocine Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Lipocine for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Lipocine can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Lipocine is way too risky over 90 days horizon | |
| Lipocine appears to be risky and price may revert if volatility continues | |
| Lipocine currently holds about 37.4 M in cash with (1.22 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.42. | |
| Lipocine has a frail financial position based on the latest SEC disclosures | |
| Latest headline from insidermonkey.com: Buy Rating Maintained on Lipocine Inc. as Target Climbs to 15 |
Lipocine Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Lipocine Stock often depends not only on the future outlook of the current and potential Lipocine's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Lipocine's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 5.4 M | |
| Cash And Short Term Investments | 21.6 M |
Lipocine Fundamentals Growth
Lipocine Stock prices reflect investors' perceptions of the future prospects and financial health of Lipocine, and Lipocine fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Lipocine Stock performance.
| Return On Equity | -0.33 | ||||
| Return On Asset | -0.21 | ||||
| Profit Margin | (1.27) % | ||||
| Operating Margin | (29.34) % | ||||
| Current Valuation | 34.73 M | ||||
| Shares Outstanding | 5.55 M | ||||
| Price To Earning | 15.80 X | ||||
| Price To Book | 3.53 X | ||||
| Price To Sales | 11.32 X | ||||
| Revenue | 11.2 M | ||||
| Gross Profit | 4.32 M | ||||
| EBITDA | (1.11 M) | ||||
| Net Income | 8.35 K | ||||
| Cash And Equivalents | 37.4 M | ||||
| Cash Per Share | 0.42 X | ||||
| Total Debt | 438.62 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 22.23 X | ||||
| Book Value Per Share | 2.61 X | ||||
| Cash Flow From Operations | (1.22 M) | ||||
| Earnings Per Share | (1.02) X | ||||
| Market Capitalization | 48.91 M | ||||
| Total Asset | 22.51 M | ||||
| Retained Earnings | (199.77 M) | ||||
| Working Capital | 20.81 M | ||||
| Current Asset | 29.41 M | ||||
| Current Liabilities | 1.57 M | ||||
About Lipocine Performance
By examining Lipocine's fundamental ratios, stakeholders can obtain critical insights into Lipocine's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Lipocine is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Capital Employed | (0.05) | (0.05) |
Things to note about Lipocine performance evaluation
Checking the ongoing alerts about Lipocine for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Lipocine help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Lipocine is way too risky over 90 days horizon | |
| Lipocine appears to be risky and price may revert if volatility continues | |
| Lipocine currently holds about 37.4 M in cash with (1.22 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.42. | |
| Lipocine has a frail financial position based on the latest SEC disclosures | |
| Latest headline from insidermonkey.com: Buy Rating Maintained on Lipocine Inc. as Target Climbs to 15 |
- Analyzing Lipocine's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Lipocine's stock is overvalued or undervalued compared to its peers.
- Examining Lipocine's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Lipocine's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Lipocine's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Lipocine's stock. These opinions can provide insight into Lipocine's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lipocine. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in services. To learn how to invest in Lipocine Stock, please use our How to Invest in Lipocine guide.You can also try the Stocks Directory module to find actively traded stocks across global markets.
Will Pharmaceuticals sector continue expanding? Could Lipocine diversify its offerings? Factors like these will boost the valuation of Lipocine. Expected growth trajectory for Lipocine significantly influences the price investors are willing to assign. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Lipocine data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (1.02) | Revenue Per Share | Quarterly Revenue Growth 5.954 | Return On Assets | Return On Equity |
Understanding Lipocine requires distinguishing between market price and book value, where the latter reflects Lipocine's accounting equity. The concept of intrinsic value - what Lipocine's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Lipocine's price substantially above or below its fundamental value.
Understanding that Lipocine's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Lipocine represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, Lipocine's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.